.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,772,219

« Back to Dashboard

Details for Patent: 7,772,219

Title:Methods of hormonal treatment utilizing extended cycle contraceptive regimens
Abstract: The present invention provides extended cycle contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin. The disclosed extended cycle contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Inventor(s): Ben-Maimon; Carole S. (Merion, PA), Hait; Howard (Wilmington, DE), Reape; Kathleen Z. (Bryn Mawr, PA), Bronnenkant; Lance J. (Synder, NY)
Assignee: Teva Women's Health, Inc. (Woodcliff Lake, NJ)
Filing Date:May 03, 2004
Application Number:10/837,268
Claims:1. A method of increasing fertility in a perimenopausal female, said method consisting essentially of administering to the female a monophasic combination of estrogen and progestin for a period of 80-90 consecutive days, in which the daily amount of estrogen is equivalent to about 10 .mu.m to about 30 .mu.g of ethinyl estradiol and in which the daily amount of progestin is equivalent to about 0.05 mg to about 0.20 mg of levonorgestrel, followed by a hormone-free period of 5-8 consecutive days, wherein neither estrogen nor progestin is administered to the female, and wherein hormone-free placebo is administered during said hormone-free period of 5-8 consecutive days, followed by administration of an agent to induce ovulation in the perimenopausal female.

2. The method of claim 1, wherein the combination of estrogen and progestin is administered for at least 84 consecutive days.

3. The method of claim 1, wherein said hormone-free placebo is administered for 7 consecutive days.

4. The method of claim 1, wherein the agent to induce ovulation in the female is selected from the group consisting of menotropins and clomiphene citrate.

5. The method of claim 4, wherein the daily amount of estrogen is equivalent to about 30 .mu.g of ethinyl estradiol, and the daily amount of progestin is equivalent to about 0.15 mg of levonorgestrel.

6. The method of claim 4, wherein said ovulation agent is a menotropin.

7. The method of claim 4, wherein said ovulation agent is clomiphene citrate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc